Survey: China's Biotech Closing In on the U.S., Already Leading in Clinical Development and Supply Chain
0xBroomberg
A Cure Innovation Index survey finds China already leads the US in clinical development and supply chain, while the US retains edges in tech transfer, capital, and talent — but respondents rank US research-funding cuts as a bigger threat than Chinese competition itself.
Six domains — who leads where?
The survey splits biotech innovation into six domains: clinical development, supply chain, tech transfer, capital & commercialization, talent, and scientific discovery.
China leads in clinical development + supply chain. The US leads in tech transfer, capital & commercialization, and talent. Scientific discovery is rated a dead heat.
This means → China's strengths are speed and manufacturing; America's are invention and monetization — the two countries dominate different links in the same chain.
How fast is China's share growing?
Georgetown University data: the US share of early-stage drug-development programs fell from 48% in 2015 to roughly 37% in 2024. China's share rose from 8% to over 32% in the same period.
Multinational pharma companies are licensing candidate molecules — drugs with early data but not yet on market — from China at an accelerating pace, with some upfront payments as low as $80 million, betting on eventual multi-billion-dollar products.
In plain terms = China went from bit player to primary supplier in a decade — its share quadrupled while America's shrank by more than ten percentage points.
How has the US government responded?
A US National Security Commission on Emerging Biotechnology report last December warned that China has built a "vertically integrated biotech ecosystem" and is well positioned to challenge US leadership.
President Trump signed the Biosecure Act, restricting federal agencies from doing business with non-US biotech firms.
This means → US policy has escalated from monitoring to legislating. Biotech is being folded into a national-security framework similar to semiconductors.
But how big is the US market itself?
Iqvia data: the US accounted for 53% of the global pharma market in 2025, up from 49% in 2021. Europe held steady at 24%. Asia-Pacific slipped from 13% to 11%.
Cure CEO Seema Kumar put it bluntly: "Commercialization is America's superpower… the buyers are in the US."
This reflects a critical reality: whoever develops the drug, the world's largest paying market is still American — and that is the US advantage hardest for any competitor to dislodge.
What do respondents see as the biggest threat?
Surprisingly, respondents ranked US research-funding cuts as a greater threat than competition from China.
Kumar called for stronger funding for the National Institutes of Health (NIH) and modernization of clinical-development infrastructure under the Bayh-Dole Act — the legal framework governing how federally funded research is commercialized — which has gone nearly 50 years without a major revision.
In plain terms = the top concern is not "the rival is too strong" but "we're starving ourselves" — if the US cuts basic-research investment, competitiveness will erode faster than any external threat can cause.
Content is for reference only, not financial advice.